#1 Clinical Trials Search in Europe

Telmisartan

This article explores the use of Telmisartan, also known as BIBR 277, in various clinical trials. These studies focus on comparing different formulations of Telmisartan, investigating its bioequivalence, and examining potential drug interactions. The trials involve healthy volunteers and patients with hypertension and nephropathy, providing valuable insights into the drug’s effectiveness and safety profile.

Table of Contents

What is Telmisartan?

Telmisartan is a medication that belongs to a class of drugs called angiotensin receptor blockers (ARBs). It is known by several brand names, including Micardis and Pritor[1]. Telmisartan is also referred to as BIBR 277 in some clinical studies[2].

What Conditions Does Telmisartan Treat?

Telmisartan is primarily used to treat the following conditions:

  • Hypertension (High Blood Pressure): This is the main condition for which telmisartan is prescribed[1].
  • Type 2 Diabetes with Hypertension: Some studies are investigating the use of telmisartan in patients who have both type 2 diabetes and high blood pressure[3].
  • Nephropathy (Kidney Disease): Research is being conducted on the effectiveness of telmisartan in hypertensive patients with kidney problems[4].
  • Cardiovascular Protection: Some studies suggest that telmisartan may have protective effects for the heart, especially after acute coronary syndrome (a term for conditions where the blood supply to the heart is suddenly blocked)[5].

How Does Telmisartan Work?

Telmisartan works by blocking the action of a hormone called angiotensin II. This hormone normally causes blood vessels to narrow, which can increase blood pressure. By blocking this hormone, telmisartan helps blood vessels relax and widen, lowering blood pressure[6].

Interestingly, telmisartan has some unique properties compared to other drugs in its class:

  • It is more lipophilic (able to dissolve in fats) than other ARBs, which means it can penetrate tissues more effectively[6].
  • It has a longer half-life (24 hours) compared to other ARBs, meaning it stays active in the body for a longer time[6].
  • It binds more tightly to its target receptor and dissociates more slowly, potentially providing a longer-lasting effect[6].

Dosage and Administration

Telmisartan is typically taken orally (by mouth) once a day. The dosage can vary depending on the condition being treated and the individual patient’s needs. Some common dosages observed in clinical trials include:

  • 40 mg daily[4]
  • 80 mg daily[6]

In some cases, telmisartan may be combined with other medications, such as hydrochlorothiazide (HCTZ), to enhance its blood pressure-lowering effects[7].

Effectiveness of Telmisartan

Several studies have shown telmisartan to be effective in treating hypertension. Its effectiveness is often measured by:

  • Changes in blood pressure readings[4]
  • Rate of blood pressure normalization (percentage of patients achieving a blood pressure below 150/90 mmHg)[4]
  • Changes in other markers of cardiovascular health, such as levels of C-reactive protein (a marker of inflammation)[5]

Potential Side Effects

While telmisartan is generally well-tolerated, like all medications, it can have side effects. Clinical trials often monitor for:

  • Adverse events (any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of the drug)[2]
  • Changes in vital signs (such as blood pressure and pulse rate)[2]
  • Abnormal changes in laboratory test results[2]
  • Changes in ECG (electrocardiogram, a test that checks for problems with the electrical activity of your heart)[2]

It’s important to note that in some studies, the side effect profile of telmisartan was described as “placebo-like,” meaning it was similar to that of an inactive substance[6].

Ongoing Research and Studies

Telmisartan continues to be the subject of various clinical trials and research studies. Some areas of ongoing investigation include:

  • Combination Therapies: Studies are looking at the effectiveness of telmisartan when combined with other medications, such as hydrochlorothiazide or amlodipine[1].
  • COVID-19 Treatment: Some researchers are investigating whether telmisartan could be beneficial in treating patients with COVID-19[6].
  • Cardiovascular Protection: Studies are examining telmisartan’s potential protective effects on the heart and blood vessels[5].
  • Kidney Protection: Research is being conducted on telmisartan’s effects in patients with kidney problems[4].

These ongoing studies aim to further our understanding of telmisartan’s benefits and potential new uses in medical treatment.

Aspect Details
Drug Name Telmisartan (BIBR 277)
Formulations Studied Tablets (erythritol-based and mannitol-based), Capsules
Main Study Objectives Bioequivalence, Antihypertensive effects, Safety, Drug interactions
Key Measurements Cmax, AUC, Tmax, Half-life, Plasma concentrations
Combination Therapies Telmisartan + Hydrochlorothiazide, Telmisartan + Omega-3
Patient Populations Healthy volunteers, Hypertensive patients with nephropathy
Safety Assessments Adverse events, Vital signs, Laboratory tests, ECG findings

FAQ

  • What is Telmisartan? Telmisartan, also known as BIBR 277, is a medication used to treat high blood pressure (hypertension). It belongs to a class of drugs called angiotensin receptor blockers (ARBs).
  • What were the main objectives of the clinical trials involving Telmisartan? The main objectives included comparing different formulations of Telmisartan (tablet vs. capsule), investigating its bioequivalence, studying its effects in patients with hypertension and nephropathy, and examining potential drug interactions with other medications.
  • How was Telmisartan administered in these trials? Telmisartan was administered in various forms, including tablets and capsules. Some trials compared different formulations, such as erythritol-based tablets vs. capsules, or mannitol-based tablets vs. capsules.
  • What were some of the key measurements taken during these trials? Key measurements included maximum drug concentration in plasma (Cmax), area under the concentration-time curve (AUC), time to reach maximum concentration (tmax), and half-life of the drug in plasma. Researchers also monitored adverse events and vital signs.
  • Were there any combination therapies studied with Telmisartan? Yes, one study investigated the combination of Telmisartan (under the brand name Pritor) with Omega-3 fatty acids. Another study looked at a fixed-dose combination of Telmisartan with Hydrochlorothiazide (HCTZ).

Ongoing Clinical Trials on Telmisartan

  • Study of stopping heart failure medications in patients with non-ischemic cardiomyopathy who responded very well to cardiac resynchronization therapy

    Recruiting

    1 1 1 1
    Investigated drugs:
    Spain

  • Study on Telmisartan for Reducing Portal Hypertension in Patients with Advanced Chronic Liver Disease

    Recruiting

    1 1
    Investigated drugs:
    Austria

  • Study on the Safety of Continuing Apixaban, Clopidogrel, and Rivaroxaban During Polyp Removal in Patients on Antiplatelet or Anticoagulant Therapy

    Recruiting

    1 1 1 1
    Investigated drugs:
    Spain

  • Study on Genotype-Guided Treatment with Carbasalate Calcium, Telmisartan, and Rivaroxaban for Patients with Peripheral Arterial Disease

    Not recruiting

    1 1 1 1
    Investigated drugs:
    The Netherlands

  • Study of XXB750 and Drug Combination for Patients with Heart Failure

    Not recruiting

    1 1
    Investigated drugs:
    Bulgaria Czechia Denmark France Germany Hungary +5

  • Study on the Effects of Metoprolol, Prasugrel, and Carbasalate Calcium in Patients with Spontaneous Coronary Artery Dissection

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on the Effects of Telmisartan, Amlodipine, and Hydrochlorothiazide on Blood Pressure in Patients with Hypertension

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Hungary Poland Slovenia

  • Study on the Effectiveness and Safety of DMX-200 with Losartan in Adults with Focal Segmental Glomerulosclerosis

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia Denmark France Germany Italy Portugal +1

Glossary

  • Bioequivalence: A state where two medications with the same active ingredient have essentially the same rate and extent of absorption in the body. This is important when comparing different formulations of the same drug.
  • Cmax: The maximum concentration of a drug observed in the blood plasma after administration. It helps determine how much of the drug reaches the bloodstream.
  • AUC (Area Under the Curve): A measure of the total exposure to a drug over time. It represents the total amount of drug absorbed by the body.
  • Tmax: The time it takes for a drug to reach its maximum concentration in the blood plasma after administration.
  • Half-life: The time it takes for the concentration of a drug in the body to reduce by half. This helps determine how long the drug stays active in the body.
  • Nephropathy: A general term for disease or damage to the kidneys, which can be caused by various conditions including diabetes and high blood pressure.
  • Hypertension: Another term for high blood pressure, a condition where the force of blood against artery walls is consistently too high.
  • Fixed-dose combination: A medication that includes two or more active ingredients combined in a single dosage form.

References

  1. https://clinicaltrials.gov/study/NCT03205137
  2. https://clinicaltrials.gov/study/NCT02262559
  3. https://clinicaltrials.gov/study/NCT04970108
  4. https://clinicaltrials.gov/study/NCT02187484
  5. https://clinicaltrials.gov/study/NCT00702936
  6. https://clinicaltrials.gov/study/NCT04355936
  7. https://clinicaltrials.gov/study/NCT02176512